Oncogenic Transcription Laboratory

<p><em>The ongoing objective of my work is to identify new and more effective treatments for patients affected with cancers of the colon, stomach and biliary tract.</em> </p> <p> I moved to New York to undertake postdoctoral training at the Montefiore Medical Center - Albert Einstein College of Medicine where I investigated the role of Wnt signaling in colon cancer progression and the use of gene expression profiling for predicting response of colon cancer cells to chemotherapy. </p> <p> I established my independent laboratory at Albert Einstein in 2001 as Assistant Professor of Medicine and was appointed Associate Professor of Medicine in 2008. I returned home to Melbourne in 2008, joining the Ludwig Institute for Cancer Research as Head of the Oncogenic Transcription Laboratory. </p> <p>I am currently Professor and Head of the Oncogenic Transcription Laboratory at the Olivia Newton-John Cancer Research Institute, where my research continues to be focused on the identification of new treatments for colon cancer, gastric cancer and cancers of biliary tract.</p> <h3>Education</h3> <p>Bachelor of Science (Honours), Genetics and Biochemistry, University of Melbourne, Australia</p> <p>Diploma, Education, University of Melbourne</p> <p>PhD, University of Melbourne</p> <h3>Current Appointments</h3> <p>Head, Gastrointestinal Cancers Program and Oncogenic Transcription Laboratory, Olivia Newton-John Cancer Research Institute </p> <p>Professor, School of Cancer Medicine, La Trobe University </p> <p>Assistant Member, Ludwig Institute for Cancer Research </p> <p>Associate Professor, Department of Medicine, University of Melbourne</p> <p> NHMRC Senior Research Fellow</p> <h3> Achievements</h3> <p>NHMRC Senior Research Fellow</p> <p>ARC Future Fellow, 2009-2013</p> <p>Moses Award for Basic Science Research, Montefiore Medical Center, New York, 2001 </p> <p>&nbsp;</p> <p>Ph: +61 3 9496 3068 </p> <p> Email: john.mariadason@onjcri.org.au</p>

<p><em>My main areas of responsibility involve management of patients with upper and lower gastrointestinal cancer in conjunction with leading the clinical trials programme at Austin Hospital and Northern Health in gastro-intestinal cancer.</em> </p> <p> My research interests involve clinical trials evaluating targeted biologic agents, including early phase trials with targeted antibodies, the development of investigator initiated clinical trials as I have developed or played a substantial role in the development of over 15 trials and the application of biomarkers to clinical trials. </p> <h3> </h3> <h3>Education</h3> <p>2002 PhD, University of Melbourne - &lsquo;Analysis of intestinal function using genetically modified mice&rsquo; </p> <p> 1998 FRACP, Fellow The Royal Australasian College of Physicians </p> <p> 1992 MRCP, Member Royal College of Physicians (UK) </p> <p> 1989 BM BCh Oxford University (UK) </p> <p> 1986 BA (Hons) Physiological Sciences Oxford University (UK)</p> <p>&nbsp;</p> <p> E: Niall.Tebbutt@onjcri.org.au </p>

<p><em>I love using cutting edge science to improve the outcomes for cancer patients who I see each day in the clinic. Every day is different as technology and treatment constantly evolves. I work i<em>n partnership with<em>&nbsp;a team of</em> laboratory scientists</em> focused on harnessing these changes.</em></p> <p>My main areas of clinical responsibility are the management of patients with genitourinary cancer and involvement in clinical trials in this patient population. I also work in drug development and early phases of drug development.</p> <p>My translational cancer research interests involve the optimisation of immunotherapy and precision medicine. This involves the identification of novel targets, refinement of biomarker assays, monitoring and evaluation of therapeutic response to therapy, and identification of resistance mechanisms to therapy. I design clinical trials that aim to improve upon standard therapies through new drugs. I analyse patient clinical outcomes and match the results of the trial to profiles of patients' immune cells and cancer cells in order to identify how to predict which patients may benefit the most from these types of treatment in the future. </p> <p>My aim is to try and find the right combination of immune therapy or targeted therapy for the right patient so that durable control of cancer may be achieved with minimal side effects. My work has appeared in publications such as the New England Journal of Medicine, Journal of Clinical Oncology, Cancer, Clinical Cancer Research and the British Journal of Cancer.</p> <h3> </h3> <h3>Education</h3> <p>MBBS (Hons), University of Melbourne, Australia </p> <p>Fellowship of the Royal Australasian College of Physicians (medical oncology) </p> <p> DMed Sc, University of Melbourne: Thesis title: Molecular determinates of therapeutic response to targeted therapies in metastatic colorectal cancer</p> <h3>Appointments</h3> <p>Associate Professor, School of Cancer Medicine, La Trobe University</p> <p> Translational Scientist, Olivia Newton-John Cancer Research Institute </p> <p>Medical Oncologist, Olivia Newton-John Cancer and Wellness Centre </p> <h3>Achievements</h3> <p> 2015 Pfizer Australia Cancer Research Grant&nbsp;</p> <p>2015 Austin Medical Research Foundation Grant</p> <p>2011-2012 Post doctoral Scholarship University of Colorado Cancer Centre&nbsp;</p> <p>2010, 2011 ASCO Cancer Foundation Merit Award&nbsp;</p> <p> 2009-2010 National Health and Medical Research Council post graduate Fellowship&nbsp;</p> <p>2009 Roche Medical Oncology Award (HOTT Fellowship)</p> <p>2009 Henry Pollack FRACP research entry scholarship&nbsp; </p> <p>2002 1st placed student final year and over all 6 years at University of Melbourne Medical School&nbsp;</p> <p> </p> <h3>Recent Publications</h3> <p>Louise Emmett, Ur Metser, Glenn Bauman, Rodney J Hicks, Andrew Weickhardt, Ian D Davis, Shonit Punwani, Gregory R Pond, Sue Siew-Chen Chua, Bao Ho, Edward Johnston, Frederic Pouliot, Andrew Scott ; A Prospective, Multi-site, International Comparison of F-18 fluoro-methyl-choline, multi-parametric magnetic resonance and Ga-68 HBED-CC (PSMA-11) in men with High-Risk Features and Biochemical Failure after Radical Prostatectomy: Clinical Performance and Patient Outcomes, Journal of Nuclear Medicine, November 2018</p> <p>A Hamid, F Ha, O Das, A Weickhardt Communicating prognosis of patients with advanced cancer between health care providers: a tertiary cancer center review of written correspondence, Annals of Palliative Medicine, 2018</p> <p>Anis Hamid, K Wilson, A Vincent&hellip;, A Weickhardt; Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration resistant prostate cancer, Asia‐Pacific Journal of Clinical Oncology, 2018</p> <p>A. Weickhardt, T Price, G Chong, V Gebski, N Pavlakis, T Johns, A Azad, E Skrinos, K Fluck, A Dobrovic, R Salemi, A Scott, J Mariadason, N Tebbutt: Dual targeting of the epidermal growth factor receptor (EGFR) using the combination of cetuximab and erlotinib: pre-clinical evaluation and results of the phase II DUX study in chemotherapy refractory, advanced colorectal cancer, Journal of Clinical Oncology 2012, May 1. Describes a novel combination of targeted therapy and potential biomarkers</p> <p>R Doebele, A Pilling, D Aisner, T. Kutateladze, A Le, A. Weickhardt, K Kondo, D Linderman, L. Heasley, W. Franklin, M Varella-Garcia, R Camidge: Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer, Clinical Cancer Research, 2012 Mar 1;18(5):1472-82 Outlines novel resistance mechanisms to targeted therapy</p> <p>&nbsp;</p> <p>Ph: +61 3 9496 9923</p> <p> E: andrew.weickhardt@onjcri.org.au</p>

<p><em>I enjoy my work as a cancer clinician because I am able to make a real-life difference everyday by caring for those suffering from cancer. As a clinician researcher, I have the opportunity to go behind-the-scenes to enhance the difference that I can make by undertaking research into new ways to care for my patients.</em> </p> <p> I qualified as a Medical Oncologist in 2013, after completing 4 years of training through the Victorian Medical Oncology network. My areas of interest are gastrointestinal cancers and skin cancers, including melanoma. I commenced my PhD higher degree shortly after completing clinical training, electing to do so at the ONJCRI because of the close relationship between clinical and laboratory research provided by the ONJ Centre. </p> <p>My current PhD research focuses on understanding the various molecular subtypes of colorectal cancer, clinical behaviour of these subtypes and their responses to treatments. I am able to study these aspects using clinical data and samples from patients previously treated on a clinical trial.</p> <h3 id="yui_3_17_2_4_1477285750618_2050">Education</h3> <p id="yui_3_17_2_4_1477285750618_2048">2013 &nbsp;&nbsp;&nbsp;FRACP, Fellowship of Royal Australasian College of Physicians (Medical Oncology)</p> <p id="yui_3_17_2_4_1477285750618_2061">2010 &nbsp;&nbsp;&nbsp;FRACGP, Fellowship of Royal Australian College of General Practitioners</p> <p id="yui_3_17_2_4_1477285750618_2063">2010 &nbsp;&nbsp;&nbsp;DipPallMed, Royal Australasian College of Physicians</p> <p id="yui_3_17_2_4_1477285750618_2065">2002 &nbsp;&nbsp;MBCHB, Bachelor of Medicine &amp; Surgery, University of Auckland, New Zealand</p> <h3>Achievements</h3> <h3 id="yui_3_17_2_4_1477285750618_2044"><span style="font-size: 16px;">2013 &nbsp;&nbsp;&nbsp;Best Trainee Poster Prize, Medical Oncology Group Australia (MOGA)</span></h3> <p id="yui_3_17_2_4_1477285750618_2069">2009 &nbsp; GP Registrar of the Year, Australian General Practice Education &amp; Training (GPET)</p>